文献速递临床试验与 GCP基础与转化研究

使用基于正念的心理干预理解和恢复纤维肌痛患者的多巴胺能功能:[18F]-DOPA PET研究。FIBRODOPA研究的研究方案——一项随机对照试验

Understanding and restoring dopaminergic function in fibromyalgia patients using a mindfulness-based psychological intervention: a [18F]-DOPA PET study. Study protocol for the FIBRODOPA study-a randomized controlled trial.
PubMed 文献 · Trials · 2021-12-01

纤维肌痛(FM)是难以治疗的慢性疼痛疾病,正念干预MORE在阿片类治疗的慢性疼痛患者中显示获益。本多中心干预性随机对照试验将64例FM患者随机分为MORE组(N=32)和非干预对照组(N=32),另设健康女性PET比较组(N=20)和仅行动态评估的健康女性组(N=15),评估MORE能否恢复FM患者多巴胺功能、减轻疼痛和情绪症状。

要点

  • MORE为每周1次、每次2小时、共8周的正念取向团体干预。
  • 主要结局为基线与干预后及3个月随访时[18F] DOPA PET测得的内源性多巴胺变化。
  • 若证实MORE可恢复多巴胺功能并减轻疼痛与情绪症状,可判断其为改善FM患者生活质量的有前景手段。

核心结论

  • 若本研究结果证实MORE可恢复多巴胺功能、减轻疼痛并改善情绪症状,则可判断MORE为改善FM患者生活质量的有前景手段。
  • 本试验结果可能为医疗保健提供者提供关于MORE作为FM可能非药物干预手段的潜在用途的信息。

研究设计与样本

  • 本研究为多中心干预性随机对照试验,设3个时间点:干预前、干预完成后及干预完成后3个月。
  • 64例FM患者随机分配至MORE干预组(N=32)或非干预对照组(N=32)。
  • 另纳入健康女性PET比较组(N=20),以及仅行动态评估的健康女性组(N=15)。
  • MORE干预为8周内每周1次、每次2小时的团体课程,共8次。
  • 干预前后FM参与者接受[18F] DOPA PET及功能磁共振成像并执行奖励任务。

主要发现

  • MORE干预在阿片类治疗的慢性疼痛患者中已显示获益,包括减轻疼痛严重程度、功能干扰及阿片类药物剂量,并恢复对奖励的神经生理和行为反应。
  • FM中已有低多巴胺状态和奖励处理受损的初步证据。
  • 关于MORE对FM患者多巴胺功能尤其对金钱奖励的多巴胺反应的影响,目前所知甚少。

关键数值与推荐

  • 主要结局为基线与干预后(非干预对照组为8周后)及3个月随访时[18F] DOPA PET测得的内源性多巴胺变化。
  • 次要结局包括:使用标准化临床量表评估的临床疼痛指标和FM症状;功能性脑改变;使用动态评估法(AA)评估日常生活中的消极和积极情感、压力及奖励体验;包括皮质醇和α-淀粉酶在内的应激生物学指标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibromyalgia (FM) is a very prevalent and debilitating chronic pain disorder that is difficult to treat. Mindfulness-based techniques are regarded as a very promising approach for the treatment of chronic pain and in particular FM. The Mindfulness-Oriented Recovery Enhancement (MORE) intervention, a mindfulness-based group intervention, has shown beneficial effects in opioid-treated chronic pain patients, including reduced pain severity, functional interference, and opioid dosing, by restoring neurophysiological and behavioral responses to reward. The first evidence for a hypodopaminergic state and impaired reward processing in FM has been reported. However, little is known about its impact on dopamine (DA) function and in particular with regard to DA responses to monetary reward in FM. The aim of the present study protocol is to evaluate if MORE is able to restore the DA function in FM patients, in particular with regard to the DA responses to reward, and to reduce pain and mood complaints in FM. METHODS: The present study is a multi-center interventional RCT with 3 time points: before the intervention, after completion of the intervention, and 3 months after completion of the intervention. Sixty-four FM patients will be randomly assigned to either the MORE intervention (N = 32) or a non-intervention control group (N = 32). Additionally, a comparison group of healthy women (N = 20) for PET measures will be enrolled and another group of healthy women (N = 15) will do the ambulatory assessments only. The MORE intervention consists of eight 2-h-long group sessions administered weekly over a period of 8 weeks. Before and after the intervention, FM participants will undergo [18F] DOPA positron emission tomography (PET) and functional MR imaging while performing a reward task. The primary outcome will be endogeneous DA changes measured with [18F] DOPA PET at baseline, after the intervention (after 8 weeks for the non-intervention control group), and at 3 months' follow-up. Secondary outcomes will be (1) clinical pain measures and FM symptoms using standardized clinical scales; (2) functional brain changes; (3) measures of negative and positive affect, stress, and reward experience in daily life using the ambulatory assessment method (AA); and (4) biological measures of stress including cortisol and alpha-amylase. DISCUSSION: If the findings of this study confirm the effectiveness of MORE in restoring DA function, reducing pain, and improving mood symptoms, MORE can be judged to be a promising means to improve the quality of life in FM patients. The findings of this trial may inform health care providers about the potential use of the MORE intervention as a possible non-pharmacological intervention for FM. TRIAL REGISTRATION: ClinicalTrials.gov NCT04451564 . Registered on 3 July 2020. The trial was prospectively registered.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ledermann K, von Känel R, Berna C, et al. Understanding and restoring dopaminergic function in fibromyalgia patients using a mindfulness-based psychological intervention: a [18F]-DOPA PET study. Study protocol for the FIBRODOPA study-a randomized controlled trial. Trials. 2021. PMID: 35078536. doi:10.1186/s13063-021-05798-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。